Global Information
회사소개 | 문의 | 위시리스트

선천성 부신과형성(CAH) : 주요 31개국 시장 예측

Epiomic Epidemiology Series: Congenital Adrenal Hyperplasia Forecast in 31 Major Markets 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 09월 상품 코드 701127
페이지 정보 영문 84 Pages
가격
US $ 6,000 ₩ 7,006,000 PDF by E-mail (Single User License)
US $ 9,000 ₩ 10,509,000 PDF by E-mail (Site License/Up to 5 Users)


선천성 부신과형성(CAH) : 주요 31개국 시장 예측 Epiomic Epidemiology Series: Congenital Adrenal Hyperplasia Forecast in 31 Major Markets 2018-2028
발행일 : 2018년 09월 페이지 정보 : 영문 84 Pages

선천성 부신과형성(CAH)은 당질코르티코이드, 광질코르티코이드, 성스테로이드 이상 생산의 원인이 되는 부신 효소 결핍에 관련된 유전성 질환입니다.

주요 31개국 시장(미국, 캐나다, 프랑스, 독일, 이탈리아, 스페인, 영국, 폴란드, 네델란드, 벨기에, 노르웨이 스웨덴, 덴마크, 오스트리아, 스위스, 아일랜드, 체코, 헝가리, 루마니아, 크로아티아, 러시아, 터키, 이집트, 일본, 중국, 한국, 인도, 호주, 브라질, 멕시코, 아르헨티나)의 선천성 부신과형성(CAH) 현재 환자수(남녀별, 연령 코호트별)에 대해 조사 분석했으며, 현재 유병률, 질환 개요, 위험인자, 질환 진단과 예후, 주요 증상과 합병증 등의 정보를 정리하여 전해드립니다.

1. 도표

2. 서론

3. 병인

4. 위험인자와 예방

5. 질환 진단

6. 변이 : 지역/민족별

7. 질환의 예후와 임상 경과

8. 질환에 관련된 주요 합병증/특징

9. 환자수 정량화 방법

10. 선천성 부신과형성(CAH) 최대 환자수

11. 선천성 부신과형성(CAH) 환자의 특징

12. 약어

13. 기타 서비스 및 솔루션

  • 보고서 및 출판물
  • 온라인 역학 데이터베이스
  • 온라인 약가 데이터베이스

14. 참고 문헌

15. 부록

LSH 18.09.28

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Congenital Adrenal Hyperplasia in 31 Major Markets

Congenital adrenal hyperplasia (CAH) is a group of genetic disorders associated with deficiencies of several adrenal enzymes which lead to abnormal production of glucocorticoids, mineralocorticoids and sex steroids. This, in turn, affects metabolism, sodium and water balance and the development of primary or secondary sex characteristics. CAH can occur in classic (severe) or non-classic (mild) forms depending on the amount of residue enzyme activity. This report covers only the classic form of the disorder.

This report provides the current prevalent population for CAH across 31 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Ireland, Czech Republic, Hungary, Romania, Croatia, Russia, Turkey, Egypt, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, CAH patients grouped by disease form have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of CAH include:

  • Hypertension, hyperlipidaemia, diabetes and venous thromboembolism
  • Osteoporosis/osteopaenia
  • Growth impairment and short stature
  • Infertility
  • Respiratory and gastrointestinal infections

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global CAH market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of CAH and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Identification of CAH patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of CAH patients.

Table of Contents

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR CONGENITAL ADRENAL HYPERPLASIA
  • FEATURES OF CONGENITAL ADRENAL HYPERPLASIA PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Typical clinical characteristics of CAH patients by type of mutation
  • Table 2. Prevalence of CAH, total (000s)
  • Table 3. Prevalence of CAH, males (000s)
  • Table 4. Prevalence of CAH, females (000s)
  • Table 5. Patients with CAH by form, total (000s)
  • Table 6. Abbreviations and acronyms used in the report
  • Table 7. USA prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 8. USA prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 9. Canada prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 10. Canada prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 11. France prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 12. France prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 13. Germany prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 14. Germany prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 15. Italy prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 16. Italy prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 17. Spain prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 18. Spain prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 19. UK prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 20. UK prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 21. Poland prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 22. Poland prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 23. Netherlands prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 24. Netherlands prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 25. Belgium prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 26. Belgium prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 27. Norway prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 28. Norway prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 29. Sweden prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 30. Sweden prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 31. Denmark prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 32. Denmark prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 33. Austria prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 34. Austria prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 35. Switzerland prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 36. Switzerland prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 37. Ireland prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 38. Ireland prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 39. Czech Republic prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 40. Czech Republic prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 41. Hungary prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 42. Hungary prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 43. Romania prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 44. Romania prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 45. Croatia prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 46. Croatia prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 47. Russia prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 48. Russia prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 49. Turkey prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 50. Turkey prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 51. Egypt prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 52. Egypt prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 53. Japan prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 54. Japan prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 55. China prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 56. China prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 57. South Korea prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 58. South Korea prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 59. India prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 60. India prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 61. Australia prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 62. Australia prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 63. Brazil prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 64. Brazil prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 65. Mexico prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 66. Mexico prevalence of CAH by 5-yr age cohort, females (000s)
  • Table 67. Argentina prevalence of CAH by 5-yr age cohort, males (000s)
  • Table 68. Argentina prevalence of CAH by 5-yr age cohort, females (000s)
Back to Top
전화 문의
F A Q
 
BCC Research